Zhejiang Huakang Pharmaceutical Co (SHSE:605077) 3-Year EBITDA Growth Rate : -6.60% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Zhejiang Huakang Pharmaceutical Co 3-Year EBITDA Growth Rate?

Zhejiang Huakang Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.33.

During the past 12 months, Zhejiang Huakang Pharmaceutical Co's average EBITDA Per Share Growth Rate was 5.40% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -6.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 3.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Zhejiang Huakang Pharmaceutical Co was 58.60% per year. The lowest was -6.60% per year. And the median was -2.20% per year.

Competitive Comparison of Zhejiang Huakang Pharmaceutical Co's 3-Year EBITDA Growth Rate

For the Chemicals subindustry, Zhejiang Huakang Pharmaceutical Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zhejiang Huakang Pharmaceutical Co's 3-Year EBITDA Growth Rate Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Zhejiang Huakang Pharmaceutical Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Zhejiang Huakang Pharmaceutical Co's 3-Year EBITDA Growth Rate falls into.

Zhejiang Huakang Pharmaceutical Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Zhejiang Huakang Pharmaceutical Co (SHSE:605077) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Zhejiang Huakang Pharmaceutical Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Zhejiang Huakang Pharmaceutical Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang Huakang Pharmaceutical Co (SHSE:605077) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Zhejiang Huakang Pharmaceutical Co Ltd (SHSE:605077) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

No. 18, Huagong Road, Huabu Town, Zhejiang Province, Kaihua County, Quzhou, CHN, 324302

Website

http://www.huakangpharma.com

Zhejiang Huakang Pharmaceutical Co Ltd is engaged in the research and development, production and sales of various functional sugar alcohols and starch sugar products such as xylitol, sorbitol, maltitol, fructose syrup and others.

Executives

Du Yong Rui	Director
Zheng Fang Ming	senior management
Jiang Xue Song	Supervisors
Yu Jian Ming	Directors, senior managers
Chen De Shui	Directors, senior managers
Xu Xiao Rong	Director
Cheng Xin Ping	Directors, senior managers
Yan Xiao Xing	Supervisors
Cao Jian Hong	Director

Zhejiang Huakang Pharmaceutical Co (SHSE:605077) Headlines

No Headlines